TORONTO, Feb. 6, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into a Product Listing Agreement ("PLA") with the province of British Columbia ("BC"), for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with BC PharmaCare is effective February 6, 2024.
Read more at newswire.caHLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.